语种选择
浏览全部资源
扫码关注微信
您当前的位置：
首页 >
文章列表页 >
177Lu-PSMA放射性配体疗法治疗前列腺癌的临床实践专家共识（2026年版）
指南与规范 | 更新时间：2026-11-12
|
177Lu-PSMA放射性配体疗法治疗前列腺癌的临床实践专家共识（2026年版）
Expert consensus of 177Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2026 edition)
- 肿瘤影像学 2026年35卷第5期 页码：695-708
- 作者机构：
- 作者简介：
- 基金信息：
DOI：10.19732/j.cnki.2096-6210.2026.05.015
中图分类号： R737.25;R445.5收稿：2026-08-26，
修回：2026-09-07，
纸质出版：2026-10-28
- 稿件说明：
移动端阅览
引用本文：中国抗癌协会肿瘤核医学专业委员会，中国医师协会核医学医师分会. 177Lu-PSMA放射性配体疗法治疗前列腺癌的临床实践专家共识（2026年版）[J].肿瘤影像学, 2026, 35（5）: 695-708.
Cite this article: Cancer Nuclear Medicine Committee of China Anti-Cancer Association, Chinese Association of Nuclear Medicine Physicians. Expert consensus of 177Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2026 edition) [J]. Oncoradiology, 2026, 35（5）:695-708.
引用本文：中国抗癌协会肿瘤核医学专业委员会，中国医师协会核医学医师分会. 177Lu-PSMA放射性配体疗法治疗前列腺癌的临床实践专家共识（2026年版）[J].肿瘤影像学, 2026, 35（5）: 695-708. DOI： 10.19732/j.cnki.2096-6210.2026.05.015.
Cite this article: Cancer Nuclear Medicine Committee of China Anti-Cancer Association, Chinese Association of Nuclear Medicine Physicians. Expert consensus of 177Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2026 edition) [J]. Oncoradiology, 2026, 35（5）:695-708. DOI： 10.19732/j.cnki.2096-6210.2026.05.015.
177Lu-PSMA放射性配体疗法治疗前列腺癌的临床实践专家共识（2026年版）
摘要
镥-177标记前列腺特异性膜抗原放射性配体疗法（
177
Lu-labeled prostate-specific membrane antigen radioligand therapy，
177
Lu
-PSMA-RLT）是前列腺癌领域的创新治疗方法，能够精准靶向原发灶及淋巴结、骨骼、内脏等组织器官转移灶细胞表面的PSMA受体，并定向递送
177
Lu释放的β射线，引起肿瘤细胞DNA的辐射损伤从而杀灭肿瘤。现阶段国内外多部前列腺癌领域权威指南与共识均推荐其用于治疗转移性前列腺癌（metastatic prostate cancer，mPC），但其诊疗规范及临床路径也需进一步明确和完善。为此中国抗癌协会肿瘤核医学专业委员会和中国医师协会核医学医师分会共同发起本共识的修订更新，结合现有的
177
Lu-PSMA-RLT注册研究结果、真实世界研究证据及国内外放射性核素临床治疗经验，根据德尔菲调研法，在适应证、患者筛选、用药不良反应管理、随访和辐射安全等方面给出推荐意见。本共识旨在为临床医师使用
177
Lu-PSMA-RLT治疗前列腺癌提供参考，为进一步制定行业相关指南奠定基础。本共识已在国际实践指南注册平台（Practice guideline REgistration for transPAREncy，PREPARE）注册（PREPARE-2026CN2053）。
Abstract
Lutetium-177-labeled prostate-specific membrane antigen radioligand therapy (
177
Lu-PSMA-RLT) is an innovative therapeutic approach in the field of prostate cancer. It can precisely target PSMA receptors on the cell surface of primary lesions and metastatic lesions in lymph nodes
bone
viscera and other tissues and organs
and selectively deliver β-rays emitted by
177
Lu to induce DNA damage in tumor cells
thereby achieving tumor cell killing. At present
177
Lu-PSMA-RLT is recommended for the treatment of metastatic prostate cancer (mPC) by multiple authoritative guidelines and consensuses in prostate cancer both domestically and internationally. However
its standardized diagnosis and treatment as well as clinical pathways need to be further established and refined. Therefore
the Cancer Nuclear Medicine Committee of Chinese Anti-Cancer Association and Chinese Association of Nuclear Medicine Physicians jointly initiated the revision and update of this consensus. Based on the available results from registered clinical trials of
177
Lu-PSMA-RLT
real-world evidence
and clinical experience with radionuclide therapy worldwide
this consensus evaluated different levels of suggestion in accordance with the results of Delphi questionnaire
and provided recommendations on indications
patient selection
management of adverse drug reactions
follow-up
and radiation safety. This consensus aims to p
rovide clinical references for clinicians in the application of
177
Lu-PSMA-RLT for prostate cancer and to lay a foundation for the further development of relevant industry guidelines. This consensus has been registered on the Practice guideline REgistration for transPAREncy (PREPARE) platform (No. PREPARE-2026CN2053).
关键词
Keywords
references
World Health Organization, International Agency for Research on Cancer. Global status report on cancer 2026: the future we choose together[R/OL]. Geneva: World Health Organization, 2026-07-08. https://www.who.int/publications/i/item/9789240123977.
Han B F, Zheng R S, Zeng H M, et al. Cancer incidence and mortality in China, 2022[J]. J Natl Cancer Cent, 2024, 4(1):47-53.
中国抗癌协会泌尿男生殖系统肿瘤专业委员会前列腺癌学组.前列腺癌筛查中国专家共识(2021年版)[J].中国癌症杂志, 2021, 31(5): 435-440.
Prostate Cancer Group, Genitourinary Oncology Committee, Chinese Anti-Cancer Association. China expert consensus on prostate cancer screening(2021 edition)[J]. China Oncol, 2021, 31(5): 435-440.
樊代明丛书主编.樊卫,石洪成.中国肿瘤整合诊治技术指南(CACA)-2023-核素治疗[M].天津:天津科学技术出版社, 2023.
Fan D M, editor-in-chief. Fan W, Shi H C. Chinese guidelines for integrative diagnosis and treatment of tumors (CACA)-2023-nuclear therapy[M]. Tianjin: Tianjin Science and Technology Press, 2023.
Amin M B, Edge S B, Greene F L, et al. AJCC Cancer Staging Manual[M]. 8th ed. New York: Springer, 2017.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer (Version 1.2024) [EB/OL]. [2026-08-26]. https://www.nccn.org.
中国临床肿瘤学会指南工作委员会组织.中国临床肿瘤学会(CSCO)前列腺癌诊疗指南-2026[M].北京:人民卫生出版社, 2026.
Organized by the Guidelines Working Committee of the Chinese Society of Clinical Oncology. Chinese Society of Clinical Oncology (CSCO) prostate cancer diagnosis and treatment guidelines-2026[M]. Beijing: People's Medical Publishing House, 2026.
樊代明.中国肿瘤整合诊治指南[M].天津:天津科学技术出版社, 2022: 61.
Fan D M. Integrated diagnosis and treatment guidelines for tumors in China[M]. Tianjin: Tianjin Science and Technology Press, 2022: 61.
Sun M, Niaz M J, Niaz M O, et al. Prostate-specific membrane antigen(PSMA)-targeted radionuclide therapies for prostate cancer[J]. Curr Oncol Rep, 2021, 23(5): 59.
Iravani A, Violet J, Azad A, et al. Lutetium-177 prostate-specific membrane antigen(PSMA)theranostics: practical nuances and intricacies[J]. Prostate Cancer Prostatic Dis, 2020, 23(1): 38-52.
Sjögreen Gleisner K, Chouin N, Gabina P M, et al. EANM dosimetry committee recommendati ons for dosimetry of 177 Lu-labelled somatostatin-receptor- and PSMA-targeting ligands [J ] . Eur J Nucl Med Mol Imaging, 2022, 49(6): 1778-1809.
Santoni M, Scarpelli M, Mazzucchelli R, et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises[J]. J Biol Regul Homeost Agents, 2014, 28(4):555-563.
Sweat S D, Pacelli A, Murphy G P, et al. Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases[J]. Urology, 1998, 52(4): 637-640.
Rajasekaran A K, Anilkumar G, Christiansen J J. Is prostate-specific membrane antigen a multifunctional protein? [J]. Am J Physiol Cell Physiol, 2005, 288(5): C975-C981.
Mannweiler S, Amersdorfer P, Trajanoski S, et al. Heterogeneity of prostate-specific membrane antigen(PSMA)expression in prostate carcinoma with distant metastasis[J]. Pathol Oncol Res, 2009, 15(2): 167-172.
Sartor O, de Bono J, Chi K N, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer[J]. N Engl J Med, 2021, 385(12): 1091-1103.
Ye D W, Song S L, Li Y H, et al. The efficacy and safety of 177Lu-PSMA-617 in Chinese patients with post-taxane metastatic castration-resistant prostate cancer: from a multicenter phase Ⅱ study[J]. J Clin Oncol, 2026, 44(S7): 181.
Morris M J, Castellano D, Herrmann K, et al. 177 Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer(PSMAfore): a phase 3, randomised, controlled trial[J ] . Lancet, 2024, 404(10459): 1227-1239.
Fizazi K, Chi K N, Shore N D, et al. Final overall survival and safety analyses of the phase Ⅲ PSMAfore trial of [ 177 Lu ] Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer[J ] . Ann Oncol, 2025, 36(11): 1319-1330.
Fizazi K, Morris M J, Shore N D, et al. Health-related quality of life, pain, and symptomatic skeletal events with [ 177 Lu ] Lu-PSMA-617 in patients with progressive metastatic castration-resistant prostate cancer(PSMAfore): an open-label, randomised, phase 3 trial[J ] . Lancet Oncol, 2025, 26(7):948-959.
Kratochwil C, Fendler W P, Eiber M, et al. Joint EANM/SNMMI procedure guideline for the use of 177 Lu-labeled PSMA-targeted radioligand-therapy(177Lu-PSMA-RLT)[J ] . Eur J Nucl Med Mol Imaging, 2023, 50(9): 2830-2845.
U.S. Food and Drug Administration. FDA approves lutetium Lu 177 vipivotide tetraxetan with androgen receptor pathway inhibitor therapy for metastatic androgen pathway modulation-naïve or-sensitive prostate cancer[EB/OL]. (2026-07-31)[2026-08-26]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy.
Emmett L, Subramaniam S, Crumbaker M, et al. [ 177 Lu ] Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer(ENZA-p): an open-label, multicentre, randomised, phase 2 trial[J ] . Lancet Oncol, 2024, 25(5): 563-571.
Emmett L, Subramaniam S, Crumbaker M, et al. Overall survival and quality of life with [ 177 Lu ] Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer(ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial[J ] . Lancet Oncol, 2025, 26(3): 291-299.
Heidegger I, Kesch C, Kretschmer A, et al. Biomarkers to personalize treatment with 177 Lu-PSMA-617 in men with metastatic castration-resistant prostate cancer-a state of the art review [J ] . Ther Adv Med Oncol, 2022, 14:17588359221081922.
Violet J, Jackson P, Ferdinandus J, et al. Dosimetry of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer:correlations between pretherapeutic imaging and whole-body tumor dosimetry with treatment outcomes[J ] . J Nucl Med, 2019, 60(4): 517-523.
Hotta M, Gafita A, Czernin J, et al. Outcome of patients with PSMA PET/CT screen failure by VISION criteria and treated with 177 Lu-PSMA therapy: a multicenter retrospective analysis [J ] . J Nucl Med, 2022, 63(10): 1484-1488.
Groener D, Nguyen C T, Baumgarten J, et al. Hematologic safety of 177 Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer[J ] . EJNMMI Res, 2021, 11(1): 61.
中华医学会核医学分会,汪静,李思进,等. 2024年全国核医学现状普查结果简报[J].中华核医学与分子影像杂志, 2024, 44(10): 617-618.
Chinese Society of Nuclear Medicine, Wang W J, Li S J. A brief report on the results of the national survey of nuclear medicine in 2024[J]. Chin J Nucl Med Mol Imaging, 2024, 44(10):617-618.
GBZ 120—2020核医学放射防护要求[S]. GBZ 120—2020 Requirements for radiological protection in nuclear medicine[S].
HJ 1188—2021核医学辐射防护与安全要求[S]. HJ 1188—2021 Requirements for radiation protection and safety in nuclear medicine[S].
Farolfi A, Armstrong W R, Djaileb L, et al. Differences and common ground in 177 Lu-PSMA radioligand therapy practice patterns: international survey of 95 theranostic centers[J ] . J Nucl Med, 2024, 65(3): 438-445.
Fendler W P, Eiber M, Beheshti M, et al. PSMA PET/CT: joint EANM procedure guideline/SNMMI procedure standard for prostate cancer imaging 2.0[J]. Eur J Nucl Med Mol Imaging, 2023, 50(5): 1466-1486.
Hope T A, Antonarakis E S, Bodei L, et al. SNMMI consensus statement on patient selection and appropriate use of 177 Lu-PSMA-617 radionuclide therapy[J ] . J Nucl Med, 2023, 64(9):1417-1423.
Huang S Y, Ong S, McKenzie D, et al. Comparison of 18 F-based PSMA radiotracers with [ 68 Ga ] Ga-PSMA-11 in PET/CT imaging of prostate cancer-a systematic review and meta-analysis[J ] . Prostate Cancer Prostatic Dis, 2024, 27(4):654-664.
Rauscher I, Krönke M, König M, et al. Matched-pair comparison of 68 Ga-PSMA-11 PET/CT and 18 F-PSMA-1007 PET/CT:frequency of pitfalls and detection efficacy in biochemical recurrence after radical prostatectomy[J ] . J Nucl Med, 2020, 61(1): 51-57.
Hofman M S, Emmett L, Sandhu S, et al. [ 177 Lu ] Lu-PSMA-617 versus cabazitaxel in patients with m etastatic castration-resistant prostate cancer(TheraP): a randomised, open-label, phase 2 trial[J ] . Lancet, 2021, 397(10276): 797-804.
European Medicines Agency. Pluvicto [lutetium ( 177 Lu) vipivotide tetraxetan ] [EB/OL ] . (2022-12-21)[2026-08-26 ] . https://www.ema.europa.eu/en/medicines/human/EPAR/pluvicto.
Ladrière T, Faudemer J, Levigoureux E, et al. Safety and therapeutic optimization of lutetium-177 based radiopharmaceuticals[J]. Pharmaceutics, 2023, 15(4): 1240.
Kratochwil C, Fendler W P, Eiber M, et al. EANM procedure guidelines for radionuclide therapy with 177 Lu-labelled PSMA-ligands( 177 Lu-PSMA-RLT)[J ] . Eur J Nucl Med Mol Imaging, 2019, 46(12): 2536-2544.
Armstrong A J, Morris M J, Antonarakis E S, et al. Trial design and objectives for prostate cancer: recommendations from the Prostate Cancer Clinical Trials Working Group 4(PCWG4)[J]. J Clin Oncol, 2026, 44(S7): 162.
Rahbar K, Bögeman M, Yordanova A, et al. Delayed response after repeated 177 Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer[J ] . Eur J Nucl Med Mol Imaging, 2018, 45(2): 243-246.
Ahmadzadehfar H, Wegen S, Yordanova A, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using [ 177 Lu ] Lu-PSMA-617[J ] . Eur J Nucl Med Mol Imaging, 2017, 44(9): 1448-1454.
Sadaghiani M S, Sheikhbahaei S, Werner R A, et al. A systematic review and meta-analysis of the effectiveness and toxicities of lutetium-177-labeled prostate-specific membrane antigen-targeted radioligand therapy in metastatic castration-resistant prostate cancer[J]. Eur Urol, 2021, 80(1): 82-94.
Spitz A, Floyd R, Sutton J, et al. Practical guidance on [ 177 Lu ] Lu-PSMA-617 treatment, including radiation safety, adverse event monitoring, and patient counseling[J ] . Clin J Oncol Nurs, 2023, 27(5): 539-547.
诺华医药科技有限公司.镥[ 177 Lu ] 特昔维匹肽注射液(派威妥 ® )说明书[Z ] . 2025.
Novartis Pharmaceutical Technology Co., Ltd. Prescribing information: Pluvicto ® (lutetium [ 177 Lu ] vipivotide tetraxetan injection)[Z ] . 2025.
Mahajan S, Grewal R K, Friedman K P, et al. Assessment of salivary gland function after 177 Lu-PSMA radioligand therapy:current concepts in imaging and management[J ] . Transl Oncol, 2022, 21: 101445.
麻广宇,巴建涛,彭程,等. 177 Lu-DOTATATE治疗神经内分泌瘤患者对环境辐射安全的研究进展[J ] .放射性核素, 2022, 35(2): 128-134.
Ma G Y, Ba J T, Peng C, et al. Research progress of 177 Lu-DOTATATE in the treatment of neuroendocrine tumor patients with environmental radiation safety[J ] . J Isot, 2022, 35(2):128-134.
Demir M, Abuqbeitah M, Uslu-Beşli L, et al. Evaluation of radiation safety in 177 Lu-PSMA therapy and development of outpatient treatment protocol[J ] . J Radiol Prot, 2016, 36(2):269-278.
Morgantetti G, Ng K L, Samaratunga H, et al. Prostate specific membrane antigen(PSMA)expression in vena cava tumour thrombi of clear cell renal cell carcinoma suggests a role for PSMA-driven tumour neoangiogenesis[J]. Transl Androl Urol, 2019, 8(S2): S147-S155.
Kulkarni H R, Singh A, Schuchardt C, et al. PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: the bad berka experience since 2013[J]. J Nucl Med, 2016, 57(S3): 97S-104S.
Herrmann K, Rahbar K, Eiber M, et al. Renal and multiorgan safety of 177 Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer in the VISION dosimetry substudy[J ] . J Nucl Med, 2024, 65(1): 71-78.
邓颖,何丽萌,孙占良,等. 177 Lu-PSMA-617治疗前列腺癌对公众人群外照射辐射剂量研究[J ] .中华核医学与分子影像杂志, 2022, 42(9): 529-533.
Deng Y, He L M, Sun Z L, et al. External exposure dose of 177 Lu-PSMA-617 to the public in the treatment of prostate cancer[J ] . Chin J Nucl Med Mol Imaging, 2022, 42(9): 529-533.
Huan Li G L, Liu H K. Radiation levels of patients with metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617. ACR, 2024.
Hope T A, Abbott A, Colucci K, et al. NANETS/SNMMI procedure standard for somatostatin receptor-based peptide receptor radionuclide therapy with 177 Lu-DOTATATE[J ] . J Nucl Med, 2019, 60(7): 937-943.
Olmstead C, Cruz K, Stodilka R, et al. Quantifying public radiation exposure related to lutetium-177 octreotate therapy for the development of a safe outpatient treatment protocol[J]. Nucl Med Commun, 2015, 36(2): 129-134.
Levart D, Kalogianni E, Corcoran B, et al. Radiation precautions for inpatient and outpatient 177 Lu-DOTATATE peptide receptor radionuclide therapy of neuroendocrine tumours[J ] . EJNMMI Phys, 2019, 6(1): 7.
Calais P J, Turner J H. Radiation safety of outpatient 177 Lu-octreotate radiopeptide therapy of neuroendocrine tumors[J ] . Ann Nucl Med, 2014, 28(6): 531-539.
Kendi A T, Halfdanarson T R, Packard A, et al. Therapy with 177Lu-DOTATATE: clinical implementation and impact on care of patients with neuroendocrine tumors [J]. AJR Am J Roentgenol, 2019, 213(2): 309-317.
Novartis Europharm Limited. Pluvicto 1 000 MBq/mL solution for injection/infusion[M]. Dublin: Novartis Europharm Limited, 2023.
Rasul S, Hacker M, Kretschmer-Chott E, et al. Clinical outcome of standardized 177 Lu-PSMA-617 therapy in metastatic prostate cancer patients receiving 7 400 MBq every 4 weeks[J ] . Eur J Nucl Med Mol Imaging, 2020, 47(3): 713-720.
Rathke H, Giesel F L, Flechsig P, et al. Repeated 177 Lu-labeled PSMA-617 radioligand therapy using treatment activities of up to 9.3 GBq[J ] . J Nucl Med, 2018, 59(3): 459-465.
Emmett L, John N, Pathmanandavel S, et al. Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer(Re-SPECT)[J]. Ther Adv Med Oncol, 2023, 15: 17588359231156392.
Mader N, Schoeler C, Pezeshkpour N, et al. Intermittent radioligand therapy with 177 Lu-PSMA-617 for oligometastatic castration-resistant prostate cancer[J ] . Cancers, 2023, 15(18):4605.
Peters S M B, Privé B M, de Bakker M, et al. Intra-therapeutic dosimetry of [ 177 Lu ] Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome[J ] . Eur J Nucl Med Mol Imaging, 2022, 49(2): 460-469.
Eapen R S, Buteau J P, Jackson P, et al. Administering [ 177 Lu ] Lu-PSMA-617 prior to radical prostatectomy in men with high-risk localised prostate cancer(LuTectomy): a single-centre, single-arm, phase 1/2 study[J ] . Eur Urol, 2024, 85(3):217-226.
Kostos L, Buteau J P, Yeung T, et al. AlphaBet: combination of Radium-223 and [ 177 Lu ] Lu-PSMA-I & T in men with metastatic castration-resistant prostate cancer(clinical trial protocol)[J ] . Front Med, 2022, 9: 1059122.
Emmett L, Subramaniam S, Joshua A M, et al. ENZA-p trial protocol: a randomized phase Ⅱ trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide(ANZUP 1901)[J]. BJU Int, 2021, 128(5): 642-651.
Patell K, Kurian M, Garcia J A, et al. Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review[J]. Expert Rev Anticancer Ther, 2023, 23(7): 731-744.
Ahmadzadehfar H, Rahbar K, Baum R P, et al. Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [ 177 Lu ] Lu-PSMA-617. A WARMTH multicenter study(the 617 trial)[J ] . Eur J Nucl Med Mol Imaging, 2021, 48(1): 113-122.
Sathekge M, Bruchertseifer F, Knoesen O, et al. 225 Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study[J ] . Eur J Nucl Med Mol Imaging, 2019, 46(1): 129-138.
Feuerecker B, Tauber R, Knorr K, et al. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA[J]. Eur Urol, 2021, 79(3): 343-350.
Lawal I O, Morgenstern A, Vorster M, et al. Hematologic toxicity profile and efficacy of [ 225 Ac ] Ac-PSMA-617 α-radioligand therapy of patients with extensive skeletal metastases of castration-resistant prostate cancer[J ] . Eur J Nucl Med Mol Imaging, 2022, 49(10): 3581-3592.
Sathekge M, Bruchertseifer F, Vorster M, et al. mCRPC patients receiving 225 Ac-PSMA-617 therapy in the post-androgen deprivation therapy setting: response to treatment and survival analysis[J ] . J Nucl Med, 2022, 63(10): 1496-1502.
中国抗癌协会肿瘤核医学专业委员会,中国医师协会核医学医师分会. 177 Lu-PSMA放射性配体疗法治疗前列腺癌的临床实践专家共识(2024年版)[J ] .中国癌症杂志, 2024, 34(7):702-714.
Nuclear Medicine Committee of China Anti-Cancer Association Cancer, Association of Nuclear Medicine Physicians Chinese. Expert consensus of 177 Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)[J ] . Chin Oncol, 2024, 34(7): 702-714.
查看原文
0
浏览量
0
下载量
0
CNKI被引量
Alert me when the article has been cited
文章被引用时，请邮件提醒。
提交
工具集
下载
- 网络PDF下载
- Meta-XML下载
参考文献导出
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
分享
分享给微信好友或者朋友圈
收藏
添加至我的专辑
关联资源
相关文章
基于治疗前后瘤内及瘤周mpMRI的Delta影像组学预测前列腺癌雄激素剥夺治疗效果的价值研究
利用18F-FDG PET显像评估不同治疗阶段前列腺癌的研究
68Ga-TBM-001 PET/CT与99mTc-MDP骨显像在前列腺癌骨转移诊断中的对比研究
超声人工智能在前列腺癌诊断中的应用进展
经直肠超声融合mpMRI导航联合弹性超声引导前列腺靶向穿刺活检的价值
相关作者
李榕
王婷
吕泓
刘晓航
周良平
顾雅佳
周冰妮
王楚
相关机构
复旦大学附属肿瘤医院病理科，复旦大学上海医学院肿瘤学系
复旦大学附属肿瘤医院放射诊断科，复旦大学上海医学院肿瘤学系
中国医学科学院北京协和医学院临床医学专业（八年制）
中国医学科学院北京协和医学院北京协和医院核医学科
成都市第七人民医院（成都医学院附属肿瘤医院）放射科
AI脑图
AI问答选择翻译语言
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
0
批量引用
导出至
BibTeXEndnoteRefManNoteExpressNoteFirst
回到顶部